Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2

Zhu, L.; Deng, Y. -Q.; Zhang, R. -R.; Cui, Z.; Sun, C. -Y.; Fan, C. -F.; Xing, X.; Huang, W.; Chen, Q.; Zhang, N. -N.; Ye, Q.; Cao, T. -S.; Wang, N.; Wang, L.; Cao, L.; Wang, H.; Kong, D.; Ma, J.; Luo, C.; Zhang, Y.; Nie, J.; Sun, Y.; Lv, Z.; Shaw, N.; Li, Q.; Li, X. -F.; Hu, J.; Xie, L.; Rao, Z.; Wang, Y.; Wang, X.; Qin, C. -F.

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Zhu, L., Deng, Y. -Q., Zhang, R. -R., Cui, Z., Sun, C. -Y., & Fan, C. -F., et al. (2020). Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2. bioRxiv, 2020.11.24.393629.
Added by: Dr. Enrique Feoli (29/11/2020, 09:01) Last edited by: Dr. Enrique Feoli (29/11/2020, 10:19)

Resource type: Journal Article
BibTeX citation key: Zhu2020
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: COVID-19
Creators: Cao, Cao, Chen, Cui, Deng, Fan, Hu, Huang, Kong, Li, Li, Luo, Lv, Ma, Nie, Qin, Rao, Shaw, Sun, Sun, Wang, Wang, Wang, Wang, Wang, Xie, Xing, Ye, Zhang, Zhang, Zhang, Zhu
Collection: bioRxiv

Views: 5/338

Abstract

Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19. Highlights SARS-CoV-2 specific antibody, HB27, blocks viral receptor binding and membrane fusion HB27 confers prophylactic and therapeutic protection against SARS-CoV-2 in mice models Rhesus macaques showed no adverse side effects when administered with HB27 Cryo-EM studies suggest that HB27 sterically occludes SARS-CoV-2 from its receptor
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli